Inactivated Avian Infectious Bronchitis Virus Strains M41 and 4–91 Provide Broad Protection Against Multiple Avian Infectious Bronchitis Strains
Open Access
Abstract
Background/Objective: The poultry industry requires extensive vaccination of chickens against IBV in an effort to prevent the disease in animals and significant economic losses. Current vaccination strategies often lack effectiveness, and the continual emergence of new IBV variants makes disease control increasingly challenging. We have developed an inactivated vaccine for poultry containing nine different antigens (Nobilis Multriva), including two IBDV strains, two ARV strains, one NDV strain, one AMPV strain, one EDSV strain and two IBV strains: M41 (genotype GI-1) and 4–91 (genotype GI-13). In this study, the IB efficacy of this novel inactivated vaccine was investigated against homologous and heterologous IBV strains. Methods: Inactivated IBV vaccine containing the M41 and 4–91 strains (Nobilis Multriva) was administered intramuscularly, either alone or following vaccine priming, in SPF and commercial chickens. Birds were challenged with homologous and heterologous IBV strains at defined ages (peak of lay, mid-lay and end of lay). Vaccine efficacy was evaluated through serological assays, clinical observations, and monitoring of egg production post-challenge. Results: This vaccine provided excellent broad protection against different IBV strains circulating in different parts of the world, including IBV M41, 4–91, QX, Q1 and Var2. Furthermore, the vaccine provided long-lasting IBV serological response against IB M41 and IB 4–91 until at least 96 weeks of age in SPF and commercial layers and breeder birds. This vaccine will allow farmers to reduce the number of vaccination moments, thereby minimizing stress to the birds, while also decreasing labor demands and the risk of human error, ultimately contributing to lower overall vaccination costs. Conclusions: Given its demonstrated broad cross-protection and sustained serological responses, this nine-valent inactivated vaccine (Nobilis Multriva) represents a key component of an effective vaccination regimen for controlling IBV infections in the poultry industry.Keywords
This publication has 26 references indexed in Scilit:
- Integument, mortality, and skeletal strength in extended production cycles for laying hens – effects of genotype and dietary zinc sourceBritish Poultry Science, 2021
- Efficacy of commercial polyvalent avian infectious bronchitis vaccines against Chinese QX-like and TW-like strain via different vaccination strategiesPoultry Science, 2020
- Vaccination against infectious bronchitis virus: A continuous challengeVeterinary Microbiology, 2017
- Global distributions and strain diversity of avian infectious bronchitis virus: a reviewAnimal Health Research Reviews, 2017
- Increasing persistency in lay and stabilising egg quality in longer laying cycles. What are the challenges?British Poultry Science, 2016
- S1 gene-based phylogeny of infectious bronchitis virus: An attempt to harmonize virus classificationInfection, Genetics and Evolution, 2016
- Infectious bronchitis virus variants: a review of the history, current situation and control measuresAvian Pathology, 2011
- Pathogenicity of a QX strain of infectious bronchitis virus in specific pathogen free and commercial broiler chickens, and evaluation of protection induced by a vaccination programme based on the Ma5 and 4/91 serotypesAvian Pathology, 2008
- Coronavirus avian infectious bronchitis virusVeterinary Research, 2007
- Neuraminidase treatment of avian infectious bronchitis coronavirus reveals a hemagglutinating activity that is dependent on sialic acid-containing receptors on erythrocytesVirology, 2004